Agilent Technologies Inc. (NYSE: A) today announced an agreement with Sangon Biotech, a leading provider of life science products and services in China. A cooperation and launch of ‘Digital Demonstration Laboratory’ ceremony was held at Agilent Technologies Shanghai (ATS) with China executives attending from both companies.
The cooperation will leverage Agilent’s comprehensive product portfolio and full workflow solutions to strengthen Sangon’s capacity for testing and analysis to better serve its customers. Together, they will actively explore advanced solutions in application areas that are essential to the biomedical and diagnostics industries, with a particular focus on promoting development in the areas of synthetic biology and multi-omics.
China’s ‘14th Five-Year Plan’ stresses the importance of biotechnology-driven economic development, which has been making a positive impact on the four pillar industries of medicine and health, bio-agriculture, bioenergy and bio-environmental protection, and bioinformatics, as well as related areas. Much of the technological development in these fields depends on nucleic acids, with nucleic acid-related biosynthesis being a key technical cornerstone.
By combining Agilent's innovative analytical technology and multi-platform solutions with Sangon’s expertise in the field of nucleic acid synthesis and sequencing, both parties aim to accelerate technological progress through cooperation in critical emerging markets. Agilent will also apply its digital and IoT technologies to help Sangon upgrade its labs to reduce energy consumption, improve experimental efficiency, and optimize experimental results, as part of Sangon’s effort to move its lab management capabilities to the next level.
“I am very happy to witness today’s cooperation ceremony. Sangon Biotech is a company with great industry influence, and Agilent's technical solutions will help Sangon Biotech to bring more competitive products to market earlier,” said Jonah Kirkwood, senior vice president and chief commercial officer at Agilent. “China has always been one of our most important markets globally. I look forward to working with our executives in China to identify new business growth opportunities, through business strategies and market opportunities, and enabling more Chinese customers to benefit from our technological innovations through long-term investments in the future.”
"We're pleased to cooperate with Sangon, a renowned giant of DNA manufacture, to help them make the most of Agilent’s comprehensive solutions to deliver an enhanced customer experience, said Yang Ting, vice president and general manager of Agilent's Greater China Commercial Organizations. “This cooperation is also a great opportunity for us to demonstrate the capacity of our digital lab solutions to improve Sangon’s lab efficiency. Through this “win-win” cooperation, we look forward to contributing to China’s continuing efforts to develop high-quality biotechnology and nucleic acid–related technologies and services."
“Agilent's technologies and instruments will greatly enhance our competitiveness, so that we can be more confident implementing technological breakthroughs and achieving technological breakthroughs as early as possible, which will ultimately benefit our customers” added Wang Luojia, CEO at Sangon Biotech.
Agilent has deep expertise and innovative technologies that support today’s digital lab transformation, with solutions that fully integrate the management of scientific data, chromatographic analysis, and laboratory processes. Agilent’s China Digital Innovation Center actively addresses challenges faced by customers in China, providing localized end-to-end workflow solutions that facilitate the creation of intelligent digital labs.